Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910211 | 0.95 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 | |
| SCHEMBL4920505 | 0.93 | CHRNB2 (0.56) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 | |
| SCHEMBL8924878 | 0.92 | CHRNB2 (0.55) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 | |
| SCHEMBL8923767 | 0.90 | CHRNB2 (0.54) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 | |
| SCHEMBL4919986 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 | |
| SCHEMBL4922485 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 | |
| SCHEMBL4921596 | 0.88 | NPC1 (0.59) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 | |
| SCHEMBL9294218 | 0.87 | NPC1 (0.57) | SMN1; SMN2NPC1RECQLRAB9ANAAA | |
| SCHEMBL9294010 | 0.87 | NPC1 (0.57) | SMN1; SMN2NPC1RECQLRAB9ANAAA | |
| SCHEMBL4924895 | 0.84 | CHRNB2 (0.55) | SMN1; SMN2NPC1RECQLRAB9ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| US-5639770-A | SUPEROXIDE INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | SMN1; SMN2 3818/4885NPC1 4153/4885RECQL 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.